JNJ 1661010 is soluble to 100 mM in DMSO and to 10 mM in ethanol.
JNJ-1661010 (681136-29-8) is a potent and selective FAAH inhibitor. Initially forms a covalent adduct with FAAH but is slowly released, IC50 = 12 nM. 100-fold selectivity for FAAH-1 over FAAH-2. Cell permeable and active in vivo. JNJ-1661010 displays analgesic activity in various animal models.
JNJ-1661010, is used to examine the contribution of endocannabinoid signaling in experimental fibrosis. In biological studies, this compound had shown to elevate the levels of arachidonoyl ethanolamide (AEA) in rat brains.
ChEBI: JNJ-1661010 is a N-arylpiperazine.
Selective, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC 50 = 12nM). Brain penetrant and active in vivo .
1) Karbarz et al. (2009), Biochemical and biological properties of 4-(3-phenyl-[1,2,4]thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase; Anesth. Analg., 108 316
